Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Perspective Therapeutics (CATX) over the last 15 years, with Q3 2025 value amounting to $294.8 million.

  • Perspective Therapeutics' Liabilities and Shareholders Equity fell 2462.67% to $294.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1064.39%. This contributed to the annual value of $341.1 million for FY2024, which is 24844.98% up from last year.
  • Perspective Therapeutics' Liabilities and Shareholders Equity amounted to $294.8 million in Q3 2025, which was down 2462.67% from $310.7 million recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' Liabilities and Shareholders Equity ranged from a high of $391.2 million in Q3 2024 and a low of $58.1 million during Q4 2022
  • In the last 5 years, Perspective Therapeutics' Liabilities and Shareholders Equity had a median value of $110.5 million in 2023 and averaged $174.5 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 75619.94% in 2021, then crashed by 2462.67% in 2025.
  • Perspective Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $67.3 million in 2021, then dropped by 13.62% to $58.1 million in 2022, then surged by 68.51% to $97.9 million in 2023, then soared by 248.45% to $341.1 million in 2024, then decreased by 13.57% to $294.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $294.8 million in Q3 2025, compared to $310.7 million in Q2 2025 and $329.3 million in Q1 2025.